Biotech Co.* (Country/Symbol)

Pharma Co. (Country/Symbol)


Disclosed Funding (M)

Terms/Details (Date)

Alliance Pharmaceutical Corp. (ALLP)

Baxter Healthcare Corp. (NYSE: BAX)

Alliance's Oxygent (perflubron emulsion) oxygen carrier in the U.S., Canada and Europe


Baxter will purchase $20M of convertible preferred stock in Alliance and is required to invest an additional $30M in such stock over the next 18 months as clinical trials progress; Alliance will also receive royalties and an ongoing share of profits (5/00)

Atrix Laboratories Inc. (ATRX)

Genmedix Ltd. (unit of Merck KgaA; Germany)

Atrix's Atrisorb and Atrisorb dental products


Genmedix will distribute Atrix's dental products in Israel and the Palestinian Authority (3/00)

Avanir Pharmaceuticals (AMEX:AVN)

SmithKline Beecham plc (UK; NYSE:SBH)

Avanir's docosonal 10% cream as a treatment for cold sores


SmithKline gains rights to market the product for cold sores in the U.S. and Canada, and will also manufacture the product; Avanir receives an up-front licensing payment and milestones of up to $25M, plus royalties on any sales; SmithKline has an option to negotiate for rights in countries not currently covered outside the U.S. and Canada (4/00)

Bio-Technology General Corp. (BTGC)

Al-Kindi Pharmaceutical Industries (Jordan)

BTG's Bio-Hep-B vaccine, Bio-Tropin, Oxandrin and BioLon


Al-Kindi has exclusive rights to distribute the BTG products in Jordan and other countries in the Middle East and North Africa; BTG will supply the products and Al-Kinda will register and market them in the licensed territory (3/00)

Bio-Technology General Corp. (BTGC)

Teva Pharmaceutical Industries Ltd. (Israel; TEVA)

BTG's recombinant human growth hormone


Teva will market the product exclusively in the U.S. under 9/99 agreement; announcement marks disclosure of first product covered under the $20M agreement (3/00)

Bio-Technology General Corp. (BTGC)

Abbott Laboratories (NYSE:ABT)

Bio-Technology's Oxandrin, an oral anabolic agent to promote weight gain


Abbott will co-market Oxandrin (FDA-approved) in the U.S. (5/00)

Celgene Corp. (CELG)

Novartis Pharma AG (Switzerland; NYSE:NVS)

D-methylphenidate, Celgene's chirally pure version of Ritalin


Novartis gains exclusive worldwide rights, excluding Canada; Celgene will receive substantial up-front fees and milestones, plus royalties; Celgene has also granted rights to all its related intellectual properties and patents; Celgene retains marketing rights to the new form and formulations of Ritalin for use in the oncology market; Novartis will fund all remaining development and marketing expenses (4/00)

Cephalon Inc. (CEPH)

Laboratoire L. Lafon (France)

Cephalon's Provigil for treatment of excessive daytime sleepiness associated with narcolepsy


Cephalon gained rights to market Provigil throughout Latin America and several countries in Asia, in addition to rights it already has in various territories, including the U.S., where the drug is approved (3/00)

Connetics Corp. (CNCT)

F.H. Faulding & Co. Ltd. (Australia)

Connetics' ConXn (recomginant human relaxin), under development as a therapy for scleroderma and peripheral vascular disease


Connetics will receive $0.5M in cash, milestones for new indications and royalties on any sales; Faulding gains rights to develop and commercialize the product in Australia (4/00)

GeneData AG* (Switzerland) TD>

Teijin Systems Technology Ltd. (Japan)

GeneData's software systems for genome analysis and genome data management


Teijin will represent GeneData and its products in the Japanese market (3/00)

Nexell Therapeutics Inc. (NEXL)

Takara Shuzo Co. Ltd. (Japan)

Nexell's cell therapy platform, with initial focus on producing a commercial gene therapy platform by combining the Nexell Lifecell X-Fold cell culture container with Takara RetroNectin (recombinant human fibronectin fragments)


Takar will exclusively distribute Nexell cell therapy products in Japan, Korea, Taiwan and China; Nexell receives a multimillion dollar up-front payment (5/00)

Orphan Medical Inc. (ORPH)

IDIS World Medicines (UK)

Orphan's Antizol (fomepizole) injection for ethylene glycol poisoning, Bulsulfex (bulsulfen) injection for use in bone marrow and stem cell transplantation, plus three other products


IDIS will distribute all of Orphan's products in countries where Orphan is not currently represented (3/00)

Orphan Medical Inc. (ORPH)

Medizinisch Handelsgesellschaft (Germany)

Busulfex (busulfen) injection for use in bone marrow and stem cell transplantation


MHG will provide Busulfex to physicians requesting the product in Germany (3/00)

United Therapeutics Corp. (UTHR)

AOP Orphan Pharmaceuticals AG (Austria)

Uniprost, a subcutaneous prostacyclin therapy in Phase III trials for treatment of late-stage pulmonary hypertension


AOP will distribute Uniprost in Austria, Switzerland, the Czech Republic, Poland, Hungary, Slovakia and Slovenia (3/00)

Salix Pharmaceuticals Group plc (Canada; TSE:SLX)

Shire Pharmaceuticals Group plc (UK; SHPGY)

Balsalazide, a treatment for ulcerative colitis


Shire will pay up to a total of $24M for exclusive rights in Austria, Belgium, Denmark, Finland, France, Germany, Iceland, Ireland, Luxembourg, Norway, the Netherlands, Switzerland, Sweden and the UK; fees include $12.1M up front ($9.6M in cash and $2.5M in equity purchase) (5/00)


# This chart does not include any marketing and/or distribution agreements that involve agricultural product development. The information in the chart covers the time period between 3/16/00 and 5/18/00.

ND = Not disclosed, reported and/or available

* Private companies are indicated with an asterisk.

Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

AMEX = American Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange; VSE =Vancouver Stock Exchange; LSE = London Stock Exchange